Genzyme's Gaucher Initiative: Global Risk and Responsibility Custom Case Solution & Analysis

1. Evidence Brief (Case Researcher)

Financial Metrics

• Ceredase production costs: $1,200 per gram of glucocerebrosidase (Exhibit 2).
• Pricing: $10 per unit; average patient requires 120 units/year, totaling $150,000 to $200,000 per patient annually (Paragraph 8).
• Genzyme revenue (1992): $153 million, with Ceredase accounting for 35% of total revenue (Exhibit 1).
• R&D expense: 18% of revenue; high reinvestment rate required for orphan drugs (Exhibit 1).

Operational Facts

• Manufacturing: Ceredase is derived from human placentas (20,000 placentas per patient/year). Requires complex, high-cost purification (Paragraph 6).
• Supply Chain: Reliance on placental sourcing creates a potential bottleneck and contamination risk (Paragraph 7).
• Product Transition: Cerezyme (recombinant version) is in clinical trials, promising higher yield and lower supply risk (Paragraph 9).

Stakeholder Positions

• Henri Termeer (CEO): Prioritizes long-term viability and patient access while maintaining high price points to fund R&D.
• Patient Advocacy Groups: Demand universal access and lower pricing, emphasizing the orphan nature of the disease.
• Global Health Authorities: Question the sustainability of high-cost orphan drugs in public health systems (Paragraph 14).

Information Gaps

• Specific cost-of-goods-sold (COGS) for the transition to Cerezyme.
• Elasticity of demand for Gaucher treatments in developing markets.

2. Strategic Analysis (Strategic Analyst)

Core Strategic Question

How does Genzyme balance its obligation to shareholders for high-margin returns with the ethical and reputational mandate to provide life-saving treatment to patients in resource-constrained global markets?

Structural Analysis

• Value Chain: The placental-based supply chain is a fundamental constraint. Recombinant production (Cerezyme) is the only path to scalability.
• Competitive Landscape: As the sole provider, Genzyme faces no direct competition but significant pressure from payers and governments regarding pricing.

Strategic Options

• Option 1: Tiered Pricing Model. Implement price discrimination based on country GDP. Trade-off: Risks parallel importation and undermines global price integrity.
• Option 2: Direct Subsidization/Donation Program. Partner with NGOs to provide Ceredase/Cerezyme to underserved regions. Trade-off: High cost; creates a dependency model that is difficult to exit.
• Option 3: Technology Transfer. License production to local manufacturers in emerging markets. Trade-off: High risk to intellectual property and product quality standards.

Preliminary Recommendation

Adopt Option 2, structured as a limited-scale patient assistance program. This preserves the premium price point in developed markets while mitigating reputational damage and addressing the immediate humanitarian crisis.

3. Implementation Roadmap (Implementation Specialist)

Critical Path

1. Formalize the Humanitarian Access Program (HAP) governance structure.
2. Establish a registry to track patient eligibility and outcomes.
3. Secure supply chain capacity to ensure that donated units do not cannibalize commercial inventory.

Key Constraints

• Supply Volatility: Placental sourcing cannot be scaled quickly to meet unexpected global demand.
• Regulatory Barriers: Varying drug approval timelines in target regions will delay delivery.

Risk-Adjusted Implementation

• Phase 1 (Months 1–6): Pilot the program in three high-need, low-regulatory-friction countries.
• Contingency: If supply for commercial markets tightens, HAP shipments are automatically paused until capacity stabilizes.

4. Executive Review and BLUF (Executive Critic)

BLUF

Genzyme must adopt a tiered pricing and philanthropic access strategy immediately. The current high-price, single-tier model is unsustainable as global scrutiny intensifies. Failure to act invites aggressive price controls and loss of patent protection in emerging markets. The company should prioritize the Cerezyme rollout to lower production costs, then use the margin differential to fund a controlled access program. This is not charity; it is a defensive necessity to protect the firm’s license to operate. The focus must remain on clinical outcomes as the metric for success, not just volume of units provided.

Dangerous Assumption

The analysis assumes that public health authorities will tolerate a high-price model if a small donation program exists. This is false. Governments will eventually demand price transparency and cost-plus models.

Unaddressed Risks

• Reputational Risk: Negative press regarding the cost of placentas versus the price of the drug (a 100x markup) could trigger political backlash.
• Political Risk: Governments in emerging markets may declare the condition a national emergency to force compulsory licensing.

Unconsidered Alternative

Create a separate, lower-cost brand identity for emerging markets using older technology (Ceredase) while reserving the premium Cerezyme brand for developed markets to maintain brand equity and price floors.

Verdict: APPROVED FOR LEADERSHIP REVIEW.